Sanofi is pushing full steam ahead with its hostile takeover try for Medivation. But rumor has it the California drugmaker may not be the only one on its target list.
Shares of rare-disease drugmaker BioMarin climbed Friday morning on speculation that that the French pharma giant could be zeroing in on it as a backup plan. At least, that’s the word from the Betaville blog, whose sources say Sanofi is growing weary of Medivation’s staunch resistance to its $52.50-per-share offer.
Of course, it’s all just buzz at this point, and as industry watchers know, buzz often amounts to nothing–especially where BioMarin is concerned. Last March, Betaville reported on a potential $65-billion Shire buyout of the San Rafael, California-based company that never came to fruition. And in 2013, the BioMarin takeover chatter was all centered on Roche, which reportedly was eyeing a $13.5 billion transaction.
Things are a little different now, though, as Betaville points out. BioMarin, like many of its biotech peers, has seen its shares fall on hard times, declining from a high near $150 last summer to just above $80 at Thursday’s close.
Sanofi, though, may have its priorities elsewhere. When laying out turnaround plans for the company early last November, new CEO Olivier Brandicourt outlined the areas where he already considered the company a market leader—rare diseases among them. Oncology, on the other hand, represented a business that needed bulking up to claim a spot in the top ranks, he said.
And that’s what a Medivation deal would do for Sanofi, which earlier this week dispatched ballots to Medivation shareholders in an attempt to wipe clean its slate of directors. The San Francisco drugmaker boasts high-flying prostate cancer pill Xtandi, a product that’s reportedly helped it draw interest from other Big Pharma players including Pfizer, Novartis and AstraZeneca.
By Carly Helfand
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
